abstract |
The present invention relates to an in vitro method for determining whether a patient infected with HCV is a responder or non-responder to the treatment with interferon-alpha and ribavirin. More specifically, the method of the invention comprises a step of determining the expression level of the IFI27, CXCL9 and G1 P2 genes in a biological sample. |